36 results about "CARDIAC THERAPY" patented technology

An introductory lead system can include a first implantable lead having a first electrode and a second implantable lead having a second electrode guided to an implant site by the first implantable lead. The second electrode can be implanted in a patient's heart at the same implant site as the first electrode or at a second implant site. The introductory lead system can be delivered to one or more implant sites using various methods, including at the Koch triangle for ventricular free wall to atrium (VfA) therapy, at the right ventricular septal wall for dual bundle branch pacing, or in the coronary vasculature for left-sided sensing and pacing.

A catheter (18A) is configured to deliver a lead (18) or other secondary device into a patient's heart (12). The catheter (18A) is configured to deliver the secondary device via a right ventricle (28) near a portion of a left bundle branch (8a) of the patient. The catheter (18A) comprises an elongate tubular member (14). The elongate tubular member (14) comprises: a proximal end (15a); a distal end (15b) sized for introduction into the body of a patient; and a lumen (14A) extending between the proximal end (15a) and the distal end (15b). The elongate tubular member (14) is preformed. The elongate tubular member (14) further includes a distal portion (150b) adjacent to the distal end (15b) and a proximal portion (99) adjacent to the proximal end (15a). The distal portion (150b) defines a curvilinear shape in a relaxed state. The curved shape comprises a curved second region (200) located in a first plane (17) and a curved fourth region (400) located in a second plane (19).

VfA cardiac therapy uses an implantable medical device or system. The implantable medical device includes a tissue piercing electrode that is implanted from the Koch triangle area of the right atrium through the right atrial endocardium and the central fibrous body into the basal region and / or septal region of the left ventricular myocardium of the patient's heart. The device may include a right atrial electrode, a right atrial motion detector, or both. The device may be fully implanted within the patient's heart or one or more leads may be used to implant the electrodes into the patient's heart. The device may be used to provide cardiac therapy, including single chamber or multi-chamber pacing, atrioventricular synchronous pacing, asynchronous pacing, triggered pacing, cardiac resynchronization pacing, or tachycardia-related therapy. Separate medical devices may be used to provide some of the functions for cardiac therapy, such as sensing, pacing, or shock therapy.

An implantable medical device delivery system includes a delivery catheter including an elongated body having a first portion defining a first lumen and a second portion defining a second lumen. An angle is defined between first and second axes defined by the first and second portions, respectively. The second axis is directed toward a left ventricular (LV) apex of a heart of a patient when the first axis is directed toward a CS. The first portion or elongated element can extend into the CS to anchor the delivery catheter relative to an orientation of the CS.

Ventricle-from-atrium (VfA) cardiac therapy may utilize a tissue-piercing electrode implanted in the left ventricular myocardium of the patient's heart from the right atrium through the right atrial endocardium and central fibrous body. The exemplary devices and methods may determine whether the tissue-piercing electrode is achieving effective left ventricular capture. Additionally, one or more pacing parameters, or paced settings, may be adjusted in view of the effective left ventricular capture determination.

A defibrillator for customizing cardiac therapy treatment of a patient while a responder is administering cardiopulmonary resuscitation (CPR) to the patient's heart. During operation, the defibrillator monitors an electrocardiogram (ECG) waveform of the patient's heart while the responder is administering CPR to the patient's heart. When the ECG waveform monitored by the defibrillator while the responder is administering CPR to the patient's heart indicates a shockable rhythm of the patient's heart, the defibrillator derives a treatment advisory from the quality of the CPR administered to the patient's heart by the responder, the vitality of the shockable rhythm of the patient's heart, and optionally other factors.

An implantable medical device includes processing circuitry, the computing apparatus configured to communicate with a plurality of implantable electrodes to sense and pace a patient's heart. The plurality of electrodes include a conduction system pacing electrode positioned in a myocardium of the patient's heart. The computing apparatus is configured to monitor local muscle impedance of the patient's heart using the cardiac conduction system electrode and adapt cardiac therapy deliverable by the implantable device based on the local muscle impedance.

A defibrillator for customizing a cardiac therapy treatment of a patient during cardio-pulmonary resuscitation (CPR) of the patient's heart by a viewer. In operation, the defibrillator monitors the ECG waveform of the patient's heart during cardiopulmonary resuscitation of the patient's heart by the eyeballer. When the ECG waveform monitored by the defibrillator indicates a shockable rhythm of the patient's heart during CPR performed by the eyeballer on the patient's heart, the defibrillator derives treatment suggestions as a function of the quality of CPR performed by the eyeballer on the patient's heart and the vitality of the shockable rhythm of the patient's heart, and optionally from other factors.

An implantable medical system may provide atrioventricular synchronous pacing using the ventricular septal wall. The system may include a ventricular electrode coupled to an intracardiac housing or a first medical lead implantable in the ventricular septal wall of the patient's heart to deliver cardiac therapy to or sense electrical activity of the left ventricle of the patient's heart and a right atrial electrode coupled to a leadlet or second medical lead to deliver cardiac therapy to or sense electrical activity of the right atrium of the patient's heart. A right ventricular electrode may be coupled to the intracardiac housing or the first medical lead and implantable in the ventricular septal wall of the patient's heart to deliver cardiac therapy to or sense electrical activity of the right ventricle of the patient's heart.

The present disclosure relates to AV synchronized VFA cardiac therapy. VfA cardiac therapy uses an implantable medical device or system. The implantable medical device comprises a tissue puncture electrode, and the tissue puncture electrode penetrates through the right atrium endocardium and the central fiber body from the Koch triangular area of the right atrium to be implanted into the basal area and / or the diaphragm area of the left ventricular myocardium of the heart of the patient. The device may include a right atrial electrode, a right atrial motion detector, or both. The device may be completely implanted within the patient's heart, or one or more leads may be used to implant the electrodes into the patient's heart. The device may be used to provide cardiac treatments, including single or multi-chamber pacing, atrioventricular synchronous pacing, asynchronous pacing, triggered pacing, cardiac resynchronous pacing, or tachycardia-related treatments. Separate medical devices may be used to provide some functionality for cardiac therapy, such as sensing, pacing, or shock therapy.

An implantable medical device (IMD) includes therapy delivery circuitry, sensing circuitry, and processing circuitry. The processing circuitry is configured to determine one or more sleep apnea therapy parameters, control the therapy delivery circuitry to deliver sleep apnea therapy via a first set of electrodes implantable within the patient in accordance with the one or more sleep apnea therapy parameters, and at least one of: (1) monitor a cardiac signal sensed with the sensing circuitry, or (2) determine one or more cardiac therapy parameters, and control the therapy delivery circuitry to deliver cardiac therapy via a second set of electrodes implantable within the patient in accordance with the one or more cardiac therapy parameters.

The invention relates to an implantable medical device (10), in particular leadless pacemaker, comprising a hermetic housing (12), a pacing electrode (14) disposed on a distal portion of the housing (12), an electronics package (16) disposed in the housing (12) configured to generate and deliver pacing output to the pacing electrode (14) and a fixation mechanism (18) arranged on the distal portion of the housing (12) adapted to engage with heart tissue to anchor the implantable medical device (10), wherein the implantable medical device (10) comprises a preset initial operation mode usable prior to and during implantation, wherein in said initial operation mode, the implantable medical device (10) is configured to disable pacing output and to run at least one electrical characterization test. The invention further relates to a cardiac therapy system and a computer-implemented method for operating an implantable medical device (10).

Devices used to access the pericardial space of the heart. In particular, there is described an apparatus to enable an operator to access the pericardial space of the heart, and deliver cardiac therapies to the pericardial space, under direct visualization through a single, small incision.

VfA cardiac therapy uses an implantable medical device or system. The implantable medical device includes a tissue-piercing electrode implanted in the basal and / or septal region of the left ventricular myocardium of the patient's heart from the triangle of Koch region of the right atrium through the right atrial endocardium and central fibrous body. The device may include a right atrial electrode, a right atrial motion detector, or both. The device may be implanted completely within the patient's heart or may use one or more leads to implant electrodes in the patient's heart. The device may be used to provide cardiac therapy, including single or multiple chamber pacing, atrioventricular synchronous pacing, asynchronous pacing, triggered pacing, cardiac resynchronization pacing, or tachycardia-related therapy. A separate medical device may be used to provide some functionality for cardiac therapy, such as sensing, pacing, or shock therapy.

An implantable medical system may provide atrioventricular synchronous pacing using the ventricular septal wall. The system may include a ventricular electrode coupled to an intracardiac housing or a first medical lead implantable in the ventricular septal wall of the patient's heart to deliver cardiac therapy to or sense electrical activity of the left ventricle of the patient's heart and a right atrial electrode coupled to a leadlet or second medical lead to deliver cardiac therapy to or sense electrical activity of the right atrium of the patient's heart. A right ventricular electrode may be coupled to the intracardiac housing or the first medical lead and implantable in the ventricular septal wall of the patient's heart to deliver cardiac therapy to or sense electrical activity of the right ventricle of the patient's heart.

The present application relates to a cardiac therapy apparatus. The cardiac therapy apparatus comprises: a subcutaneous defibrillation assembly, which comprises a first control component and is configured to sense a global activation event of a heart, generate a far-field sense signal indicative of the global activation event, and deliver a defibrillation wave to a patient when the patient has malignant arrhythmia; and a leadless myocardial stimulation assembly, which comprises a second control component and is configured to sense a local activation event of myocardium at a predetermined stimulation position, generate a local sense signal indicative of the local activation event, and apply to the predetermined stimulation position an electrical stimulation impulse for enhancing the myocardial contractility, wherein the first control component is coupled to the second control component through wireless communication, and the first control component and / or the second control component are / is configured to determine, at least according to the far-field sense signal and the local sense signal, whether to apply the electrical stimulation impulse to the predetermined stimulation position.

A cardiac life support method for adapting a basic cardiac life support device to deliver an advanced cardiac therapy to a patient. The method involves establishing communication between the basic cardiac life support device and an advanced cardiac therapy adapter when the basic cardiac life support device is connected a patient whereby the cardiac life support adapter derives the advanced cardiac therapy from data representative of the cardiac status of the patient received from the basic cardiac life support device, and the cardiac life support adapter manages a delivery by the basic cardiac life support device of the advanced cardiac therapy to the patient.

Provided are methods and materials for assaying known and candidate therapeutics for inotropic cardiac effects in one or more in vitro assay formats comprising preloaded cardiac tissues and / or organoids.

A cardiac therapy device includes a stimulation circuit configured to generate a non-excitatory electrical signal that improves a condition of heart failure in a human patient when the non-excitatory electrical signal is applied to ventricular tissue during a ventricular refractory period of the ventricular tissue; an atrial arrhythmia detection circuit; and a decision circuit that controls the stimulation circuit to deliver the signal when the atrial arrhythmia detection circuit detects an atrial arrhythmia.

VfA cardiac treatment uses an implantable medical device or system. The implantable medical device includes a tissue puncture electrode, which is implanted in the basal region and / or septal region of the left ventricular myocardium of the patient's heart through the right atrial endocardium and the central fiber body from the Koch triangle of the right atrium. The device may include a right atrial electrode, a right atrial motion detector, or both. The device may be completely implanted in the patient's heart, or one or more leads may be used to implant the electrode into the patient's heart. The device can be used to provide cardiac treatment, including single-chamber or multi-chamber pacing, atrioventricular synchronous pacing, asynchronous pacing, triggered pacing, cardiac resynchronization pacing, or tachycardia-related treatment. A separate medical device can be used to provide some functions for cardiac treatment, such as sensing, pacing, or electric shock therapy.

A surgical access port including an outer sheath having a tapered distal end; an inner sleeve fitting inside the outer sheath; and a cannulated core fitting inside the inner sleeve; wherein a distal opening of the outer sheath is configured to expand when the inner sleeve is inserted into the outer sheath, and wherein the cannulated core forms a first working channel and a second working channel between a first end of the cannulated core and an opposing second end of the cannulated core.

The utility model discloses a special dosing device for heart treatment, which relates to the technical field of medicine taking, and comprises a containing mechanism, an ejection mechanism and an adjusting mechanism, the containing mechanism is used for storing medicines, the ejection mechanism is connected with the containing mechanism, the ejection mechanism is used for ejecting the medicines in the containing mechanism, and the adjusting mechanism is connected with the containing mechanism. The adjusting mechanism is arranged in the ejection mechanism and used for changing the number of the medicine ejected by the ejection mechanism. The containing mechanism moves upwards and then moves downwards, so that the ejection mechanism ejects the medicine out of the containing mechanism from the bottom end of the containing mechanism, a patient can take the medicine more conveniently, cap screwing operation is avoided, closing of the containing mechanism is completed while medicine taking is completed, and convenience of medicine taking is further improved.

Atria-to-ventricle (VfA) cardiac therapy can utilize a tissue-penetrating electrode implanted from the right atrium through the right atrial endothelium and the central fibrous body into the left ventricular myocardium of a patient's heart. The example apparatus and method can determine whether the tissue-penetrating electrode is achieving effective left ventricular capture. Additionally, one or more pacing parameters or pacing settings can be adjusted based on an effective left ventricular capture determination.

Systems and methods can monitor electrical activity of a patient's heart during delivery of a cardiac therapy using electrodes, and determine a degree of left posterior fascicle capture based on the monitored electrical activity. The systems and methods can adjust the cardiac therapy based on the degree of left posterior fascicle capture.

The invention discloses a psychological assessment and intervention system and method based on Go behavior analysis, and relates to the technical field of psychological health, the system comprises a chess manual data acquisition module, a digital cardiac therapy all-in-one machine, a psychological behavior quantitative analysis model and a man-machine combination study and judgment platform. The method comprises the following steps: collecting chess manual data generated when a user plays chess on a general go platform; the chess manual is imported into the all-in-one machine, each step of chess is classified into a local hand, a nostrum, a custom hand or a faint hand through the quantitative analysis model and mapped to a preset psychological behavior mode, and a preliminary quantitative report is generated; and performing deep interpretation and verification by a professional analyst in combination with a chess context to form a final evaluation conclusion. The system can also perform targeted intervention through an ABC psychological enabling engine, and comprises a cognitive remodeling module, a behavior construction module and a social adaptation module. Psychological assessment is realized by quantitatively analyzing the Go behaviors, and the assessment accuracy is improved in combination with man-machine research and judgment, so that a basis is provided for psychological intervention.

This invention relates to an apparatus and a method for optimizing cardiac stimulation instants of a patient, wherein a signal processing chain and a set of transformations are applied to provide robust, denoised and coherent electrogram (EGM) cycles An orthogonal (uncorrelated) transformation of observed EGMs provides an improved combination of available EGMs in terms of information content, maximizes sensitivity to changes in cardiac therapy configurations and is invariant to anatomy and lead positions of each patient. Furthermore, an original feature extraction is applied after orthogonal transformation of the EGMs and allows for calculation of a set of markers that can be better interpreted and used for optimizing the stimulation instants for a given patient.

In some instances, a method for controlling the delivery of cardiac therapy and cardiac sensing by a medical device system that includes electrodes for delivering cardiac therapy may include storing in a memory of the medical device system: corresponding values for each of a plurality of cardiac therapy and / or sensing parameters, and corresponding modifications associated with each of a plurality of cardiac position states for at least one of the cardiac therapy and / or sensing parameters. The method may further include: determining a current cardiac position state of the plurality of cardiac position states of the patient; modifying at least one cardiac therapy and / or sensing parameter value according to the modification associated with the current cardiac position state; and controlling the delivery of the cardiac therapy and / or cardiac sensing according to the modified at least one cardiac therapy and / or sensing parameter value.

The present application relates to a cardiac therapy device including a subcutaneous defibrillation unit including a first control component configured to detect global cardiac excitation events, generate far-field detected signals indicative of the global excitation events, and deliver defibrillation waves to a patient when the patient experiences a malignant arrhythmia, and a leadless cardiac stimulation unit including a second control component configured to detect local myocardial excitation events at predetermined stimulation sites, generate local detected signals indicative of the local excitation events, and apply stimulating electrical pulses to the predetermined stimulation sites to enhance myocardial contractility, wherein the first control component is wirelessly coupled to the second control component, and the first control component and / or the second control component is configured to determine whether to apply stimulating electrical pulses to the predetermined stimulation sites based on at least the far-field detected signals and the local detected signals.

This invention discloses a method comprising locating a Koch triangle region in the right atrium of a patient's heart; securing at least one electrode of an implantable lead or device from the Koch triangle region to cardiac tissue for delivery of atrium-to-ventricle (VfA) cardiac therapy; and testing the position or depth of the at least one electrode to configure the VfA cardiac therapy. Locating the target implantation area in the Koch triangle region may include detecting atrial slow path potentials (ASP) or atrial pacing outputs.